GARDskin approved by OECD

THE FIRST AND ONLY Genomics and Machine-learning based in vitro skin sensitization assay

Get a quote

Sensitization Testing with GARD®

Regulatory Toxicity Testing

Biological Evaluation of Medical Devices

The GARD® technology: An holistic approach

Learn more about the improved accuracy and human relevance

SenzaGen provides state-of-the-art non-animal tests for assessing a substance’s allergenicity. With excellent predictivity, the tests meet needs in several industries and help companies develop, produce and deliver safer, ethical and more sustainable products.

GLP Compliant Laboratory

READ MORE

Meet SenzaGen.

ESTIV 2026

June 29 - July 2Maastricht

Eurotox 2026

September 13 - September 16Vienna
EVENT CALENDAR

Press Releases

2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
17 Mar, 2026
News
IR
English
Corporate Information
Other Corporate Information
mfn-ext-nq
mfn-ext-nq-company-announcement
SenzaGen to present strong GARD®skin data at the world’s largest toxicology conference together with leading industry partners
10 Mar, 2026
News
IR
English
Corporate Information
Other Corporate Information
mfn-ext-nq
mfn-ext-nq-company-announcement
Growing interest in non-animal respiratory allergy testing – GARD®air data presented by industry leaders
13 Feb, 2026
News
IR
English
Regulatory
MAR
Corporate Information
Other Corporate Information
mfn-ext-nq
mfn-ext-nq-inside-information
SenzaGen carries out a directed issue of approximately SEK 17.5 million to the institutional investor Eiffel Investment Group
PreviousNext

News Posts

Subscribe


Prenumerera